Sir, Recently the American Academy of Pediatrics (AAP) issued guidelines on screening and treatment of hypercholesterolemia in children [1] . According to the new indications, statins are now recommended for younger patients (from 8 years instead of 10 as previously recommended) belonging to the same two risk categories addressed in the previous AAP statement: (1) LDL persistently above 160 mg/dl despite diet therapy, with other risk factors for cardiovascular disease such as overweight, hypertension, smoking, or familial hypercholesterolemia or (2) LDL >190 mg/dl, despite diet therapy, without other risk factors for cardiovascular disease. Based on these indications, a 9-year-old overweight child with LDL, say, at 175 mg/dl after 6 months of appropriate dietetic restrictions, should start treatment with statins.
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We think that the evidence to support such an indication is not strong enough and that a word of caution is necessary. Almost all clinical trials of treatment with statins carried out in children have considered patients affected by familial hypercholesterolemia [2] . For the relatively small group of patients affected by this condition, a pharmacological intervention is recommended because of the strong correlation with adult-onset cardiovascular disease [3] . Children with high LDL cholesterol and other risk factors for cardiovascular disease, i.e., the category of patients now included in the risk categories proposed by AAP, represent a far more numerous population group, but in this group of patients, information on long-term efficacy and safety of treatment with statins is scanty. With respect to the efficacy, as children don't have heart attacks, investigators have looked at the effects of statins on endothelial dysfunction and carotid intimal medial thickness, early markers for atherosclerosis in adults. Controlled studies in children show that statins improve these parameters [4, 5] , but there is no evidence of efficacy on prevention of mortality or morbidity related to adult-onset cardiovascular disease. This is a crucial point since the use of statins in primary prevention of cardiovascular disease appears to be controversial in adults, too [6] .
With respect to safety, clinical trials demonstrated a safety profile of statins for a mean time of treatment of 27 weeks (range 6-96) [2] , which is an extremely short period of time, especially if life-long treatment is proposed, as it is in the AAP statement. The possibility of adverse effects, which may become apparent only after a long exposure to treatment, also considering the greater cumulative dose when treatment starts in childhood rather than in adult life, cannot be neglected.
Long-term treatments also pose the problem of compliance. It is well known that compliance with preventive treatment is much more difficult to obtain than with curative treatment [7] but surprisingly this issue was not addressed by the AAP statement.
For children belonging to high-risk groups, we believe that further research is needed before we extend the indications for long-term treatment with statins to hypercholesterolemic children and adolescents. Meanwhile, from a public health perspective, we would rather emphasize the need for a more comprehensive approach to address the epidemic of childhood obesity [8] and to prevent the related adult-onset risks [9] .
